Search Results
Your search for ,New matches 16916 pages
Showing 15651 - 15700FDA Approves New Oral Medication for the Treatment of Refractory Metastatic Colorectal Cancer
The U.S. Food and Drug Administration today approved trifluridine/tipiracil (Lonsurf) for patients with metastatic colorectal cancer who have been previously treated with chemotherapy and biologic therapy and are no longer responding to treatment. The new agent is an oral combination of...
ASCO Statement: Recommendations for Obesity Clinical Trials in Cancer Survivors
As reported in the Journal of Clinical Oncology by Ligibel et al, ASCO has issued a statement providing recommendations for obesity clinical trials in cancer survivors. ASCO convened the Research Summit on Advancing Obesity Clinical Trials in Cancer Survivors in November 2014. The meeting involved...
Breast Cancer Symposium: Recurrence Rates for Ductal Carcinoma in Situ Treated Between 1978–2010
A new retrospective analysis explored local recurrence rates for women with ductal carcinoma in situ (DCIS) treated between 1978 and 2010. In the research (Abstract 32) by Van Zee et al, to be presented September 25 at the 2015 Breast Cancer Symposium, in San Francisco, investigators evaluated a...
Decreased Mortality for Men With Unfavorable-Risk Prostate Cancer and Moderate or Severe Comorbidities Treated With Radiotherapy Alone
Men with unfavorable-risk prostate cancer and moderate or severe comorbidities had significantly decreased overall and cardiac mortality when treated with radiotherapy alone vs radiotherapy and androgen-deprivation therapy, according to a study described in a research letter in JAMA. In the letter, ...
Study Questions Cost-Effectiveness of Universal BRCA Screening
Women who are carriers of mutated BRCA genes are known to have a significantly higher risk for developing breast and ovarian cancers than those who do not have the mutations. A viewpoint published recently in JAMA Oncology by researchers at the University of California Los Angeles questioned...
Antifungal Agent Increases Risk of Cutaneous Squamous Cell Carcinoma in Some Lung Transplant Recipients
Voriconazole, commonly used to prevent and treat fungal infections in lung transplant recipients, significantly increases the risk for cutaneous squamous cell carcinoma in this population, according to a new study by University of California San Francisco researchers. The team recommends physicians ...
Study Finds CD38-Targeted Antibody Daratumumab Active in Relapsed Multiple Myeloma
In a phase I/II trial reported in The New England Journal of Medicine, Lokhorst et al found that the CD38-targeting human IgG1κ monoclonal antibody daratumumab had an acceptable safety profile and produced durable responses in relapsed multiple myeloma. Study Details In the dose-escalation...
Pancreatic Cancer Action Network and AACR Invite Applications for 2016 Research Grants
The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network announced the opening of the 2016 Research Grants Program to support early-career investigators to focus on pancreatic cancer. Two grant mechanisms, the Pathway to Leadership Grant and the Career...
New Genetic Mutation Leading to Protein Repression Identified in Melanoma Cancer Cells
There is strong evidence that the protein complex APC/C may function as a tumor suppressor in multiple cancers including lymphoma, colorectal cancer, breast cancer, and now, melanoma. A new study has revealed that a genetic mutation leading to repression of a specific protein, Cdh1, which interacts ...
Prophylactic Surgery Rates Rise in Men With Breast Cancer
The number of men with breast cancer who undergo surgery to remove the unaffected breast has risen sharply, according to a new report by the American Cancer Society and Dana-Farber Cancer Institute researchers. The report, published by Jemal et al in JAMA Surgery, is the first to identify the...
Long-Term Remissions Reported in CLL Personalized Cell Therapy Trial
In the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL), 8 of 14 patients responded to the therapy, with some complete remissions continuing past 4.5 years. These results, published by Porter et al in Science Translational...
Researchers Discover Novel Marker for Retinoblastoma
A new marker already linked to other types of cancer was found to play a role in the most common childhood primary tumor inside the eye, researchers at the University of Michigan Health System have found. Their findings were published by Khan et al in Laboratory Investigation. Retinoblastoma is a...
Pembrolizumab Treatment May Cause Immune Cells to Express Markers of Reinvigoration
Treating patients with metastatic melanoma with the immunotherapy drug pembrolizumab (Keytruda) caused immune cells called CD8-positive T cells in the patient’s blood to express markers of reinvigoration, according to data being presented at the CRI-CIMT-EATI-AACR International Cancer...
Preclinical Study Shows Small-Protein Immunotherapeutic May Have More Antitumor Activity Than Conventional Antibodies
An engineered high-affinity programmed cell death protein 1 (PD-1) small protein that can bind to PD-L1 (PD-1 ligand) on tumors was found to be a more effective anticancer immunotherapeutic than conventional anti–PD-L1 antibodies, and this small protein was more effective in synergizing with...
Frequency of Certain Immune Cells in Blood May Predict Response to Pembrolizumab in Metastatic Melanoma
Among patients with metastatic melanoma treated with the immunotherapy drug pembrolizumab (Keytruda), those whose cancer responded to the treatment had a higher frequency of T cells that were positive for the proteins CD8, PD-1, and Bim (CD8+PD-1+Bim+ T cells) in blood samples taken immediately...
Chemotherapy Pretreatment May Boost Effectiveness of CAR T-Cell Therapy in Patients With Lymphoma and Leukemia
A small phase I/IIa study of third-generation CD19 CAR (chimeric-antigen receptor) T-cell therapy combined with chemotherapy pretreatment has resulted in complete responses in 6 of the 11 patients with relapsed or refractory lymphoma and leukemia enrolled in the study. Although CAR T-cell...
Long-Term Infusion of Immunotherapy May Reduce Pain in Children With High-Risk Neuroblastoma
Changing the infusion delivery method of the monoclonal antibody ch14.18/CHO (dinutuximab-beta, the European counterpart of dinutuximab [Unituxin]) in combination with interleukin-2 and oral 13-cis-retinoic acid from short-term infusion to long-term infusion in the treatment of children with...
Immune System–Boosting Agent May Reduce Early-Stage Melanoma Recurrences
Among patients with clinically stage I or stage II melanoma, those treated with the immune system–boosting agent CpG-B were less likely to experience recurrence of their disease than those who received placebo, according to results from two randomized, placebo-controlled phase II clinical...
Brazilian Wasp Venom May Be Active Against Cancer Cells
The social wasp Polybia paulista protects itself against predators by producing venom known to contain a powerful cancer-fighting ingredient. A Biophysical Journal study published by Bueno Leite et al revealed how the venom's toxin—called MP1 (Polybia-MP1)—may selectively kill cancer...
Genetic Sequencing May Impact Treatment for Children With Rare, Aggressive Cancers
For children with rare, aggressive, and advanced cancer, precision medicine may help doctors determine their best treatment options, a new study found. Using information from a patient's entire genome helped to suggest personalized treatment options for nearly half of children with cancer and...
Study Explores Link Between Allele Expression and Risk of Graft-vs-Host Disease in Transplant Recipients
In a study reported in The New England Journal of Medicine, Petersdorf et al found a greater risk of acute graft-vs-host disease among hematopoietic cell transplant recipients with the high-expression rs9277534G allele linked to mismatched HLA-DPB1 who received transplants from donors with the...
AACR’s Cancer Progress Report Details Major Advances in Cancer and Rising Costs of Treatment
The American Association for Cancer Research (AACR) 2015 Cancer Progress Report highlighted the accelerated pace of the number of U.S. Food and Drug Administration (FDA)-approved targeted therapies over the past 5 years, which reached 52 this year; the dramatic increase in the 5-year survival rate...
Persistent Leukemia-Associated Mutations After Induction Therapy Predict Poorer Outcome in AML
In a study reported in JAMA, Klco et al found that persistence of leukemia-associated mutations in ≥ 5% of bone marrow cells at remission predicted poorer outcome among patients with acute myeloid leukemia (AML), including those with intermediate-risk disease. Study Details In the study,...
Statistical Model May Identify Patients Most Likely to Benefit From Mesothelioma Surgery
A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma, according to a report published by Leuzzi et al in The Annals of Thoracic Surgery. Malignant pleural mesothelioma is an aggressive...
MicroRNA Panel Shows Early Potential as Biomarker of Pancreatic Precancers
Assessing blood plasma levels of certain microRNAs (miRNAs) distinguished individuals with noninvasive pancreatic precancers from healthy individuals and discriminated between patients with high-risk and low-risk neoplasms, according to a preliminary, proof-of-principle study published by...
BRAF Inhibition Successful in Relapsed/Refractory BRAF V600E–Mutant Hairy Cell Leukemia
In two phase II studies reported in The New England Journal of Medicine, Tiacci et al found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia who relapsed after treatment with a purine analog or who had...
FDA Grants Priority Review to Ixazomib for Patients With Relapsed/Refractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New Drug Application for the investigational oral proteasome inhibitor ixazomib for the treatment of patients with relapsed or refractory multiple myeloma, Takeda Pharmaceuticals announced. The New Drug...
Internationally Acclaimed Cancer Researcher, Gianni Bonadonna, MD, Dies at 81
Gianni Bonadonna, MD, was considered the “Father of Italian Oncology,” but his scientific contributions to the field and his generous collegial spirit extended far beyond the shores of his native land. Dr. Bonadonna was at the forefront in the battle to convince the surgical...
WCLC: Cetuximab May Improve Survival in Some Patients With EGFR-Positive Squamous NSCLC
Analysis of a large phase III trial (S0819) suggested that adding the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab (Erbitux) to chemotherapy benefits survival in patients with squamous cell non–small cell lung cancer (NSCLC) with tumors positive...
WCLC: New Study Reveals Genomic Architecture of EGFR Mutations in Lung Cancer
Epidermal growth factor receptor (EGFR) mutations are one of the most common driver oncogenes in lung cancer, typified by high response rates when treated with tyrosine kinase inhibitors and median progression-free survival of 10 months, commonly due to emergence of T790M. The genomic...
New Agent Targeting Epigenetic Modifications Shows Activity in Advanced Cancer
In a dose-escalation phase I study reported in The Lancet Oncology, Reid et al found that RRx-001, a representative of a new class of compounds called dinitroazetidines (sourced from the aerospace industry) that act on the tumor microenvironment, had activity in advanced cancers and a promising...
FDA Grants Alectinib Priority Review for ALK‑Positive Lung Cancer
Genentech announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive,...
Final Results of NO16968 Trial Show Improved Overall Survival With Adjuvant XELOX vs Bolus 5-FU/Leucovorin in Stage III Colon Cancer
As reported by Schmoll et al in the Journal of Clinical Oncology, the final results of the phase III NO16968 trial showed that adjuvant therapy with XELOX (capecitabine, oxaliplatin) improved overall survival vs fluorouracil (5-FU)/leucovorin in patients with resected stage III colon cancer....
WCLC: IASLC Issues Statement on Tobacco Control and Smoking Cessation
The International Association for the Study of Lung Cancer (IASLC) issued a new statement on Tobacco Control and Smoking Cessation on September 7 at the 16th World Conference on Lung Cancer (WCLC) in Denver, Colorado. The statement calls for higher taxes on tobacco products; comprehensive...
WCLC: Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma
The standard of care for malignant pleural mesothelioma may be poised for change, judging by results from a study (Abstract ORAL11.01) by the French Cooperative Thoracic Intergroup. The addition of bevacizumab (Avastin) in the first-line setting to the current standard of care, pemetrexed...
WCLC: Impact of Time to Drug Approval on Potential Years of Life Lost
Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the United States and 260 life-years worldwide, according to research (Abstract ORAL12.05) presented on September 7 at the 16th World Conference on Lung Cancer hosted by the International Association of the...
BRAF V600 Mutation Appears to Be Targetable Oncogene in Some but Not All Nonmelanoma Cancers
In a phase II histology-independent basket study reported in The New England Journal of Medicine, Hyman et al found that the BRAF V600 kinase inhibitor vemurafenib (Zelboraf) exhibited activity in some but not all nonmelanoma cancers with BRAF V600 mutations. Study Details In the study, 122...
Survivors of Childhood Cancer Have High Risk of Recurrent Stroke
Recent evidence suggests that survivors of childhood cancer have a high risk of suffering a stroke at a surprisingly young age. A new study from the UC San Francisco Pediatric Brain Center shows that childhood cancer survivors suffering one stroke have double the risk of suffering a second stroke...
Increased Risk of Cancers After Age 40 in Childhood Cancer Survivors
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Turcotte et al found that survivors of childhood cancer are at increased risk of subsequent malignant neoplasms after age 40 years. Study Details The study involved data from 3,171 survivors of...
FDA Approves Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) approved rolapitant (Varubi) to prevent delayed-phase chemotherapy-induced nausea and vomiting. Rolapitant is approved in adults in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of...
Call for APOS 2016 Award Nominations
The American Psychosocial Oncology Society (APOS) will be celebrating 30 years of psychosocial oncology at the 13th Annual APOS Conference, to be held March 3 to 5, 2016, in San Diego. Colleagues, mentors, students, and others who have made an impact on psychosocial oncology can be nominated for an ...
New 'Mutation-Tracking' Blood Test Could Predict Breast Cancer Relapse
Scientists have developed a blood test for breast cancer that may be able to identify which patients will suffer a relapse after treatment, months before tumors are visible on hospital scans. The test may uncover small numbers of residual cancer cells that have resisted therapy by detecting cancer...
Combination of Chemotherapy and T-Cell Immunotherapy May Provide Novel Treatment Strategy for Glioblastoma
A preclinical study has found that a combination of decitabine and T-cell immunotherapy demonstrated antitumor activity against glioblastomas in mouse models and was about 50% effective at curing the disease. The results, reported by Everson et al in Neuro-Oncology, show an innovative,...
FDA Accepts for Priority Review the Biologics License Application for Elotuzumab for the Treatment of Relapsed Multiple Myeloma
Bristol-Myers Squibb and AbbVie today announced that the U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for elotuzumab, an investigational signaling lymphocyte activation molecule (SLAMF7)-directed immunostimulatory antibody, for the...
ASCO Releases Updated Policy Statement on Genetic and Genomic Testing for Cancer Susceptibility
The American Society of Clinical Oncology (ASCO) issued an updated policy statement on genetic and genomic testing for cancer susceptibility. Published in the Journal of Clinical Oncology, the statement reviews the ways in which new technologies are transforming the assessment and identification of ...
AAV2 Virus May Be Linked to Hepatocellular Carcinoma in Patients With No History of Cirrhosis or Other Risk Factors
More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus. Researchers at Inserm, the Paris Public Hospitals (AP-HP), Paris...
Activity of Colony-Stimulating Factor-1 Receptor Kinase Inhibitor in Tenosynovial Giant Cell Tumors
In a phase I study reported in The New England Journal of Medicine, Tap et al found that a newly developed inhibitor of colony-stimulating factor-1 receptor (CSF1R) kinase showed activity in tenosynovial giant cell tumors. CSF1 gene expression is elevated in most such tumors. The structure of the...
Fertility Concerns and Side Effects Keep Many Young Women With Breast Cancer From Taking or Completing Tamoxifen
Concerns about fertility kept one-third of young women with breast cancer surveyed in a recent study from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer recurrence. In addition, the study found fertility concerns led one-quarter of women who started...
Study Validates Method for Patient Reporting of Cancer Drug–Related Adverse Events
In cancer clinical trials, doctors typically report side effects that patients experience—not patients themselves. Previous research has shown that doctors underreport these symptoms. Ethan Basch, MD, MSc, Director of the UNC Lineberger Cancer Outcomes Research Program and Associate...
Preclinical and Clinical Evidence of Lack of Sprouting Angiogenesis in Development of Lymph Node Metastases
In preclinical and clinical studies reported in the Journal of the National Cancer Institute, Jeong et al found a lack of sprouting angiogenesis in the formation of lymph node metastases, suggesting a potential mechanism for resistance to antiangiogenic treatments in adjuvant settings. The study...
